Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges

Area of Science:

• Oncology
• Endocrinology
• Medicinal Chemistry

Background:

• Estrogen receptor alpha (ERα) is a key target for ER-positive breast cancer.
• Tamoxifen and aromatase inhibitors (AIs) are successful but face therapeutic resistance.
• Novel strategies like protein degradation and covalent inhibition are needed for ERα targeting.

Purpose of the Study:

• To review recent advancements in ERα-targeting therapeutics.
• To focus on compounds that have progressed to clinical development.
• To highlight novel approaches beyond traditional endocrine therapies.

Main Methods:

• Literature review of recent scientific publications and clinical trial data.
• Focus on oral selective ER degraders (SERDs), complete estrogen receptor antagonists (CERANs), selective estrogen receptor covalent antagonists (SERCAs), and PROTAC ER degraders.
• Analysis of compounds advanced into clinical development for ERα-targeted therapy.

Main Results:

• Several novel ERα-targeting agents, including oral SERDs, CERANs, SERCAs, and PROTACs, are in development.
• These new modalities offer alternative mechanisms to overcome endocrine resistance.
• A number of these promising compounds have entered clinical trials, indicating therapeutic potential.

Conclusions:

• Emerging ERα-targeting drugs, such as oral SERDs and PROTACs, represent a significant advancement in breast cancer treatment.
• These novel agents hold promise for overcoming resistance to current endocrine therapies.
• Further clinical development is crucial to establish the efficacy and safety of these new therapeutic strategies.